This study is looking at a new way to treat head and neck squamous cell cancer (HNSCC) that has come back or spread. It uses a special vaccine called tumor membrane vesicle (TMV) vaccine that helps the body fight the cancer. Some patients will also get a medicine called pembrolizumab, which helps the immune system attack cancer cells.
Who Can Join: You must be at least 18, have a type of head and neck cancer, and have gone through certain treatments before. Your cancer must have come back or spread, and you need to have enough tumor tissue saved from surgery to make the vaccines.
- The study lasts up to 1 year, with visits every 3 weeks.
- You'll get either the TMV vaccine alone or with pembrolizumab.
- Expect regular tests like blood samples, scans, and heart checks.
After treatment, there are follow-up visits for up to 12 months. This study aims to find the best dose and see how well the treatment works. Before joining, make sure you're okay with the procedures and understand the possible risks and benefits.